Full Library

Posaconazole, a triazole antifungal commonly used for the treatment and prevention of invasive fungal infections, is available in IV, oral suspension and oral delayed-release (DR) tablet formulations.1–3 Of the oral formulations, the DR tablet is favoured owing to its superior bioavailability, once-daily dosing and reliable absorption regardless of gastric acidity.4 Even when dosed appropriately, posaconazole oral solution often does not achieve therapeutic levels.5 This complicates administration in patients unable to swallow tablets whole and in whom long-term IV administration is undesirable. Posaconazole DR tablets are labelled as ‘do not crush,’ largely due to extrapolated concern that crushing the DR matrix may lead to a ‘dose dump’ and altered bioavailability.6,7 Recently, several case series have demonstrated success with crushing and administering the DR tablets via enteral feeding tubes, thus prompting a practice change across our health system.8–10